Amarin Corp Plc (AMRN)

[Jt0082]

Yes am aware of Avenu medical and ellipsis. Vascular access guidelines in the US and around the world recommend a fistula in the forearm (radio cephalic (RC) AVF) as the first access. The reason is that failures in the wrist/forearm can be followed by alternative forms of access higher in the arm, such as an AVG (Humacyte) or an AVF in the upper arm, either made surgically or with one of the percutaneous approaches (everlinQ or Ellipsys). In addition, a functioning fistula at the wrist/forearm is associated with the best outcomes. To that end, the trials conducted with everlinQ and Ellipsys from Avenu specifically excluded patients who were candidates for a RC AVF, and the technology is not suited for making a fistula below the elbow, hence their second/third line positioning. AVG’s, including Humacyte’s, have not been shown to offer advantages versus a functioning fistula, and therefore I think should be viewed as second/third line options.

Let’s take this off the AMRN board if you want? Would be keen to hear your wife’s views...